UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/578,613	03/12/2007	Masatoshi Tohata	289779US0PCT	3580	
22850 7590 10/15/2010 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER		
			POPA, ILEANA		
ALEAANDRIA, VA 22314			ART UNIT	PAPER NUMBER	
		1633			
			NOTIFICATION DATE	DELIVERY MODE	
			10/15/2010	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/578,613	TOHATA ET AL.	
Examiner	Art Unit	

	ILEANA POPA	1633				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress			
THE REPLY FILED 09 September 2010 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.				
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A replies: (1) an amendment, affidavit al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
 a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Acono event, however, will the statutory period for reply expire late Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f) 	dvisory Action, or (2) the date set forth in ter than SIX MONTHS from the mailing o). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.			
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as			
2. The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the				
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cor (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or	sideration and/or search (see NOT v);	E below);				
(d) They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).						
 4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowed. 			·			
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-15. Claim(s) withdrawn from consideration:	」 will not be entered, or b) ⊠ will	•	_			
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a			
10. The affidavit or other evidence is entered. An explanation	n of the status of the claims after er	ntry is below or attach	ed.			
REQUEST FOR RECONSIDERATION/OTHER 11. ☐ The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:			
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s) 13. ☑ Other: <u>see the continuaiton sheet</u> .						
	/Ileana Popa/ Primary Examiner, Art U	nit 1633				

Claims 1-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ferrari et al. (WO 03/083125), in view of both Gardan et al. (Mol. Microbiol., 1997, 24: 825-837) and Hakamada et al. (Biosci. Biotechnol. Biochem., 2000, 64: 2281-2289).

Applicant's arguments are not new and were previously addressed. The applicant asserts that the examiner did not explain why one of skill in the art would be motivated to make the proposed modifications. In response, it is noted that the explanation was provided in the final Office action of 06/17/2010. The applicant argues that the examiner failed to provide any reason why one of skill in the art wouldl have selectively inactivated rocA, F, or D. In response, it is noted that Ferrari specifically teach inactivating at least one gene selected from the group consisting of rocA, rocF, rocD, ycgN, and ycgM (see p. 91, lines 1 and 2). Thus, one of skill in the art would have had to select from a finite, small number of genes a(nd not from a numerous number of genes, as the applicant argues). One of skill in the art would have found it obvious to select rocA, F, or D (i.e., three genes) out of a group consisting of only five genes.